Vanda Pharmaceuticals Inc.

Drug pipeline (5)

Asset	Stage	Revenue	Trials	Status
ILOPERIDONE	approved	—	12	approved
Milsaperidone	approved	—	4	approved
PONESIMOD	approved	—	7	approved
Tasimelteon	approved	—	25	approved
Tradipitant	approved	—	19	approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (76)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT03291041	phase2	completed	2016-07-01	2017-11-01	Vanda Pharmaceuticals	A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
NCT01402076	phase1	completed	2011-08-01	2011-08-01	Vanda Pharmaceuticals	A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
NCT04712734	phase1	completed	2021-01-13	2022-08-30	Vanda Pharmaceuticals	A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
NCT05344365	phase2	withdrawn	2022-06-01	2023-11-01	Vanda Pharmaceuticals	A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
NCT07446439	phase3	recruiting	2026-03-27	2026-12-01	Vanda Pharmaceuticals	A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

FDA applications (6)

Application

Type

Applicant

Products

NDA 022192

NDA

VANDA PHARMACEUTICALS INC

NDA 205677

NDA

VANDA PHARMACEUTICALS INC

NDA 213498

NDA

VANDA PHARMACEUTICALS INC

NDA 214517

NDA

VANDA PHARMACEUTICALS INC

NDA 220152

NDA

VANDA PHARMACEUTICALS INC